Lyell Immunopharma (NASDAQ:LYEL) Sets New 52-Week Low - Time to Sell?

Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) hit a new 52-week low on Monday . The stock traded as low as $0.40 and last traded at $9.73, with a volume of 865368 shares trading hands. The stock had previously closed at $0.40.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a "neutral" rating and set a $20.00 target price on shares of Lyell Immunopharma in a research note on Wednesday, April 16th.

Lyell Immunopharma Stock Down 2.8%

The company has a 50 day moving average of $0.60 and a two-hundred day moving average of $0.65. The firm has a market cap of $2.36 billion, a P/E ratio of -10.11 and a beta of -0.25.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($3.60) earnings per share for the quarter, beating the consensus estimate of ($3.80) by $0.20. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. The business had revenue of $0.01 million during the quarter. Research analysts expect that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.

Insider Activity at Lyell Immunopharma

In related news, CFO Charles W. Newton purchased 10,000 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was acquired at an average price of $11.20 per share, for a total transaction of $112,000.00. Following the transaction, the chief financial officer now directly owns 10,000 shares of the company's stock, valued at $112,000. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Lynn Seely purchased 8,750 shares of the firm's stock in a transaction that occurred on Friday, March 14th. The stock was bought at an average price of $12.20 per share, with a total value of $106,750.00. Following the transaction, the chief executive officer now directly owns 35,625 shares in the company, valued at $434,625. This trade represents a 32.56% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 38,432 shares of company stock valued at $449,508 over the last 90 days. 25.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Lyell Immunopharma

A number of hedge funds and other institutional investors have recently modified their holdings of LYEL. Decheng Capital LLC acquired a new position in shares of Lyell Immunopharma in the 4th quarter valued at $7,622,000. Foresite Capital Management V LLC acquired a new position in shares of Lyell Immunopharma in the 4th quarter valued at $5,205,000. venBio Partners LLC acquired a new position in shares of Lyell Immunopharma in the 4th quarter valued at $4,545,000. Almitas Capital LLC boosted its position in shares of Lyell Immunopharma by 136.3% in the 1st quarter. Almitas Capital LLC now owns 2,482,606 shares of the company's stock valued at $1,336,000 after purchasing an additional 1,432,086 shares during the period. Finally, Renaissance Technologies LLC boosted its position in shares of Lyell Immunopharma by 716.7% in the 4th quarter. Renaissance Technologies LLC now owns 1,612,146 shares of the company's stock valued at $1,032,000 after purchasing an additional 1,414,746 shares during the period. Institutional investors and hedge funds own 66.05% of the company's stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.